Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Loratadine

FDA-approved product (tablet, oral), marketed as Alavert, Children's Claritin, Claritin and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Loratadine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Allergic rhinitis
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antihistamines for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Loratadine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Loratadine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria

    NCT00525382 · start 2003-08

    Registered record
    Registry ID
    NCT00525382
    Conditions
    Urticaria
    Interventions
    levocetirizine dihydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-08
    Completion
    2004-03
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrticaria
    Interventionlevocetirizine dihydrochloride
    PhasePhase 3
    Registry statusCompleted

  • Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)

    NCT00963469 · start 2001-08

    Registered record
    Registry ID
    NCT00963469
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    montelukast sodium; Comparator: loratadine; Comparator: placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-08
    Completion
    2001-11
    Enrolment
    1,079

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    Interventionmontelukast sodium; Comparator: loratadine; Comparator: placebo
    PhasePhase 3
    Registry statusCompleted

  • Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

    NCT02932774 · start 2001-03

    Registered record
    Registry ID
    NCT02932774
    Conditions
    Allergic Rhinitis; Hay Fever; SAR; Rhinitis, Allergic, Seasonal
    Interventions
    Cetirizine; Loratadine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-03
    Completion
    2001-07
    Enrolment
    683

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Hay Fever; SAR; Rhinitis, Allergic, Seasonal
    InterventionCetirizine; Loratadine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)

    NCT00960141 · start 2000-08

    Registered record
    Registry ID
    NCT00960141
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    montelukast sodium; Comparator: loratadine; Comparator: placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-08
    Completion
    2000-11
    Enrolment
    829

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    Interventionmontelukast sodium; Comparator: loratadine; Comparator: placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

    NCT03855228 · start 1995-03-01

    Registered record
    Registry ID
    NCT03855228
    Conditions
    Rhinitis, Allergic
    Interventions
    Mometasone furoate nasal spray (MFNS); Loratadine; Placebo nasal spray; Placebo tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-03-01
    Completion
    1995-08-07
    Enrolment
    704

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic
    InterventionMometasone furoate nasal spray (MFNS); Loratadine; Placebo nasal spray; Placebo tablet
    PhasePhase 3
    Registry statusCompleted